MTOR and acute lymphoblastic leukemia: Further, using a panel of 378 kinase inhibitors, we observed that ALL cell lines that were either sensitive (NALM6 and 697) or resistant (TANOUE and JURKAT) to dexamethasone were highly responsive to inhibitors targeting Aurora kinases, PLKs, and PI3K/mTOR pathway components (Supplementary Fig. 3).